Rudi Pauwels is a Belgian pharmacologist and serial biotechnology entrepreneur specializing in virology, antiviral drug development, and personalized medicine, with a career spanning over 35 years in academia and industry. He is best known for his pioneering research on HIV inhibitors and for co-founding several influential biotech firms that advanced treatments for infectious diseases and diagnostics.
Pauwels earned his PhD from KU Leuven and conducted early research at the Rega Institute for Medical Research, where he focused on virology and developed key assays for detecting anti-HIV compounds. His academic contributions include over 127 publications with more than 22,000 citations, earning an h-index of 71 in microbiology, particularly for work on non-nucleoside reverse transcriptase inhibitors and viral replication mechanisms. Notable papers, such as his 1988 tetrazolium-based colorimetric assay for anti-HIV screening (cited over 2,500 times), revolutionized in vitro testing for antiviral agents.
In 1994, Pauwels co-founded Tibotec, a company specializing in retroviral therapies that was later acquired by Janssen Pharmaceuticals, leading to breakthroughs like the HIV drug etravirine. He also co-established Virco for viral resistance diagnostics, Galapagos Genomics for drug discovery, and Biocartis in 2007 for molecular diagnostics, serving as its CEO until 2017. More recently, Pauwels has focused on global health access through the Praesens Foundation, which he created to support diagnostics and treatments in low-resource settings, and serves as Partner and Executive Chairman at ANeuroTech, advancing nanotechnology for brain disorders.
Rudi Pauwels
Rudi Pauwels